Literature DB >> 27648125

Exogenous NAD(+) administration significantly protects against myocardial ischemia/reperfusion injury in rat model.

Youjun Zhang1, Ban Wang2, Xingli Fu3, Shaofeng Guan1, Wenzheng Han1, Jie Zhang2, Qian Gan1, Weiyi Fang1, Weihai Ying2, Xinkai Qu1.   

Abstract

Acute myocardial infarction is one of the leading causes for death around the world. Although essential for successful interventional therapy, it is inevitably complicated by reperfusion injury. Thus effective approaches to reduce ischemia/reperfusion (I/R) injury are still critically needed. To test our hypothesis that intravenous administration of NAD(+) can attenuate I/R injury by reducing apoptotic damage and enhancing antioxidant capacity, we used a rat mode of myocardial I/R. Our study found that administration of 10-20 mg/kg NAD(+) can dose dependently reduce myocardial infarct induced by I/R, with an approximately 85% reduction of the infarct at the dosage of 20 mg/kg NAD(+). We further found that the injection of NAD(+) can significantly decrease I/R-induced apoptotic damage in the heart: NAD(+) administration can both decrease the TUNEL signals, Bax, cleaved caspase-3 levels and increase the Bcl-XL levels in the rats that are subjected to myocardial I/R injury. NAD(+) administration can also significantly attenuate I/R-induced decreases in SOD activity and SOD-2 protein levels in the hearts. NAD(+) can profoundly decrease myocardial I/R injury at least partially by attenuating apoptotic damage and enhancing the antioxidant capacity, thus suggesting that NAD(+) may become a promising therapeutic agent for myocardial I/R injury.

Entities:  

Keywords:  Myocardial ischemia/reperfusion; NAD+; antioxidation; apoptosis; infarction

Year:  2016        PMID: 27648125      PMCID: PMC5009387     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  26 in total

1.  Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling.

Authors:  Liming Yu; Feijiang Li; Guolong Zhao; Yang Yang; Zhenxiao Jin; Mengen Zhai; Wenjun Yu; Lin Zhao; Wensheng Chen; Weixun Duan; Shiqiang Yu
Journal:  Apoptosis       Date:  2015-06       Impact factor: 4.677

2.  CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis.

Authors:  Ting Zhang; Yan Zhang; Mingyao Cui; Li Jin; Yimei Wang; Fengxiang Lv; Yuli Liu; Wen Zheng; Haibao Shang; Jun Zhang; Mao Zhang; Hongkun Wu; Jiaojiao Guo; Xiuqin Zhang; Xinli Hu; Chun-Mei Cao; Rui-Ping Xiao
Journal:  Nat Med       Date:  2016-01-04       Impact factor: 53.440

Review 3.  Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process.

Authors:  A L Moens; M J Claeys; J P Timmermans; C J Vrints
Journal:  Int J Cardiol       Date:  2005-04-20       Impact factor: 4.164

4.  Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart.

Authors:  F Di Lisa; R Menabò; M Canton; M Barile; P Bernardi
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

5.  Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia.

Authors:  Weihai Ying; Guangwei Wei; Dongmin Wang; Qing Wang; Xiannan Tang; Jian Shi; Peng Zhang; Huafei Lu
Journal:  Front Biosci       Date:  2007-01-01

6.  Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension.

Authors:  Eva Nozik-Grayck; Crystal Woods; Joann M Taylor; Richard K P Benninger; Richard D Johnson; Leah R Villegas; Kurt R Stenmark; David G Harrison; Susan M Majka; David Irwin; Kathryn N Farrow
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-17       Impact factor: 5.464

7.  Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway.

Authors:  Vinodkumar B Pillai; Nagalingam R Sundaresan; Gene Kim; Madhu Gupta; Senthilkumar B Rajamohan; Jyothish B Pillai; Sadhana Samant; P V Ravindra; Ayman Isbatan; Mahesh P Gupta
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

8.  Analytical characteristics of commercial cardiac troponin I and T immunoassays in serum from rats, dogs, and monkeys with induced acute myocardial injury.

Authors:  Fred S Apple; MaryAnn M Murakami; Ranka Ler; Dana Walker; Malcolm York
Journal:  Clin Chem       Date:  2008-10-09       Impact factor: 8.327

9.  NAD(+) administration decreases doxorubicin-induced liver damage of mice by enhancing antioxidation capacity and decreasing DNA damage.

Authors:  Ban Wang; Yingxin Ma; Xiaoni Kong; Xianting Ding; Hongchen Gu; Tianqing Chu; Weihai Ying
Journal:  Chem Biol Interact       Date:  2014-02-01       Impact factor: 5.192

10.  NAD⁺-carrying mesoporous silica nanoparticles can prevent oxidative stress-induced energy failures of both rodent astrocytes and PC12 cells.

Authors:  Heyu Chen; Yao Wang; Jixi Zhang; Yingxin Ma; Caixia Wang; Ying Zhou; Hongchen Gu; Weihai Ying
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

View more
  17 in total

1.  NAD metabolism in aging and cancer.

Authors:  John Wr Kincaid; Nathan A Berger
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-05

2.  Exogenous supplemental NAD+ protect myocardium against myocardial ischemic/reperfusion injury in swine model.

Authors:  Xinrong Zhai; Wenzheng Han; Ming Wang; Shaofeng Guan; Xinkai Qu
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Combination of nicotinamide mononucleotide and troxerutin induces full protection against doxorubicin-induced cardiotoxicity by modulating mitochondrial biogenesis and inflammatory response.

Authors:  Ahmad Jamei Khosroshahi; Behnaz Mokhtari; Reza Badalzadeh
Journal:  Mol Biol Rep       Date:  2022-07-17       Impact factor: 2.742

Review 4.  Emerging potential benefits of modulating NAD+ metabolism in cardiovascular disease.

Authors:  Daniel S Matasic; Charles Brenner; Barry London
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

Review 5.  The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging.

Authors:  Eduardo N Chini; Claudia C S Chini; Jair Machado Espindola Netto; Guilherme C de Oliveira; Wim van Schooten
Journal:  Trends Pharmacol Sci       Date:  2018-02-23       Impact factor: 14.819

6.  Nicotinamide mononucleotide and melatonin counteract myocardial ischemia-reperfusion injury by activating SIRT3/FOXO1 and reducing apoptosis in aged male rats.

Authors:  Aida Jafari-Azad; Leila Hosseini; Mojgan Rajabi; Poul Flemming Høilund-Carlsen; Manouchehr Seyedi Vafaee; Saeid Feyzizadeh; Reza Badalzadeh
Journal:  Mol Biol Rep       Date:  2021-04-17       Impact factor: 2.316

7.  The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD+ decline.

Authors:  Claudia Chini; Kelly A Hogan; Gina M Warner; Mariana G Tarragó; Thais R Peclat; Tamar Tchkonia; James L Kirkland; Eduardo Chini
Journal:  Biochem Biophys Res Commun       Date:  2019-04-08       Impact factor: 3.322

Review 8.  The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Thais Ribeiro Peclat; Bo Shi; John Varga; Eduardo Nunes Chini
Journal:  Curr Opin Rheumatol       Date:  2020-11       Impact factor: 4.941

Review 9.  MiR-222 in Cardiovascular Diseases: Physiology and Pathology.

Authors:  Shengguang Ding; Haitao Huang; Yiming Xu; Hao Zhu; Chongjun Zhong
Journal:  Biomed Res Int       Date:  2017-01-03       Impact factor: 3.411

10.  Oxidative stress induces cell death partially by decreasing both mRNA and protein levels of nicotinamide phosphoribosyltransferase in differentiated PC12 cells.

Authors:  Cuiyan Zhou; Weihai Ying
Journal:  PeerJ       Date:  2021-05-14       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.